Press release
Alzheimer's Disease Market: Epidemiology, Therapies, Companies, DelveInsight | Biogen/Eisai, BioVie, AB Science, Eli Lilly and Company, Cassava Sciences, TauRx Therapeutics, Novo Nordisk, KeifeRx, Eli
Alzheimer's Disease Market
The market for Alzheimer's Disease is anticipated to expand in the coming years, driven by the development of emerging therapies.
DelveInsight has released a comprehensive report titled "Alzheimer's Disease - Market Insights, Epidemiology, and Market Forecast 2034", providing detailed analysis of Alzheimer's Disease, including historical and projected epidemiology, as well as market trends across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. Key companies featured include Biogen/Eisai, BioVie, AB Science, Eli Lilly, Cassava Sciences, TauRx Therapeutics, Novo Nordisk, KeifeRx, AriBio, Cerecin, Alzheon, Neurim Pharmaceuticals, Athira Pharma, Annovis Bio, Anavex Life Sciences, AgeneBio, Eisai, and Suven Life Sciences.
Discover about the Alzheimer's Disease market report [https://www.delveinsight.com/report-store/alzheimers-disease-japan-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Some of the key facts of the Alzheimer's Disease Market Report:
*
According to DelveInsight's 2024 estimates, Alzheimer's disease affected around 16 million diagnosed individuals across the 7MM, highlighting its substantial impact on public health systems and the urgent need for innovative treatment approaches.
*
Within the EU4 and the UK, Germany reported the highest number of diagnosed prevalent cases, accounting for about 30% of the total, followed by France with 24%. DelveInsight analysts project that Alzheimer's cases will continue to rise over the coming years.
*
In the United States, nearly 2.4 million men and 5 million women were diagnosed with Alzheimer's in 2024, with numbers expected to increase by 2034.
*
Epidemiological analysis further shows that in the EU4 and the UK, the 75-84 age group recorded the highest prevalence of Alzheimer's in 2024-about 2 million cases-while individuals under 65 accounted for the lowest prevalence, with around 130,000 cases.
*
Additionally, in Japan, there were an estimated 2.5 million diagnosed cases of agitation related to Alzheimer's disease in 2024-a behavioral complication characterized by restlessness, aggression, anxiety, and irritability. This symptom significantly reduces patient quality of life and places considerable emotional and physical strain on caregivers, with case numbers expected to grow by 2034.
*
DelveInsight analysts estimated that in 2024, there were approximately 16 million diagnosed cases of Alzheimer's disease across the 7MM. The United States alone accounted for about 44% of these cases-around 7 million-with projections indicating a continued rise by 2034. This increasing prevalence highlights the growing healthcare burden Alzheimer's poses in the U.S.
*
In the U.S., age-specific distribution in 2024 showed that the under-65 age group had nearly 180,000 cases, the 65-74 group had approximately 1.6 million, the 75-84 age group recorded around 3 million, and the 85+ population had about 2.5 million cases.
*
Key Alzheimer's Disease companies such as Biogen/Eisai, BioVie, AB Science, Eli Lilly and Company, Cassava Sciences, TauRx Therapeutics, Novo Nordisk, KeifeRx, Eli Lilly, AriBio, Cerecin, Alzheon, Neurim Pharmaceuticals, Athira Pharma, Annovis Bio, Anavex Life Sciences, AgeneBio, Eisai, Suven Life Sciences, and others are evaluating new drugs for Alzheimer's Disease to improve the treatment landscape.
Alzheimer's Disease Overview
Alzheimer's disease is a chronic, progressive neurological condition that gradually impairs memory, thinking, and other cognitive functions. It is the most common cause of dementia, accounting for approximately 60-80% of all cases. While it typically develops in individuals over the age of 65, early-onset Alzheimer's can occasionally affect people in their 40s or 50s.
Early signs often include memory loss that disrupts everyday activities, followed by confusion, difficulty with language, poor judgment, and changes in behavior. The precise cause of the disease is still unclear, but it is strongly linked to the buildup of amyloid beta plaques and tau tangles in the brain, which interferes with neural communication and triggers brain cell death. Advancing age and family history are among the primary risk factors associated with the condition.
Discover how the Alzheimer's Disease market is rising in the coming years @ https://www.delveinsight.com/sample-request/alzheimers-disease-japan-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Scope of the Alzheimer's Disease Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Alzheimer's Disease Companies: Biogen/Eisai, BioVie, AB Science, Eli Lilly and Company, Cassava Sciences, TauRx Therapeutics, Novo Nordisk, KeifeRx, Eli Lilly, AriBio, Cerecin, Alzheon, Neurim Pharmaceuticals, Athira Pharma, Annovis Bio, Anavex Life Sciences, AgeneBio, Eisai, Suven Life Sciences, and others
*
Alzheimer's Disease Therapeutic Assessment: Alzheimer's Disease current marketed and Alzheimer's Disease emerging therapies
*
Alzheimer's Disease Market Dynamics: Alzheimer's Disease market drivers and Alzheimer's Disease market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Alzheimer's Disease Unmet Needs, KOL's views, Analyst's views, Alzheimer's Disease Market Access and Reimbursement
To know what's more in our Alzheimer's Disease report, visit https://www.delveinsight.com/report-store/alzheimers-disease-japan-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Key benefits of the Alzheimer's Disease Market Report:
*
Alzheimer's Disease market report covers a descriptive overview and comprehensive insight of the Alzheimer's Disease Epidemiology and Alzheimer's Disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
*
The Alzheimer's Disease market report provides insights into the current and emerging therapies.
*
The Alzheimer's Disease market report provides a global historical and forecasted market covering drug outreach in 7MM.
*
The Alzheimer's Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Alzheimer's Disease market.
Got queries? Click here to know more about the Alzheimer's Disease market Landscape [https://www.delveinsight.com/sample-request/alzheimers-disease-japan-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Alzheimer's Disease Patient Share (%) Overview at a Glance
5. Alzheimer's Disease Market Overview at a Glance
6. Alzheimer's Disease Disease Background and Overview
7. Alzheimer's Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Alzheimer's Disease
9. Alzheimer's Disease Current Treatment and Medical Practices
10. Unmet Needs
11. Alzheimer's Disease Emerging Therapies
12. Alzheimer's Disease Market Outlook
13. Country-Wise Alzheimer's Disease Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Alzheimer's Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Click here to read more about Alzheimer's Disease Market Outlook 2034 [https://www.delveinsight.com/report-store/alzheimers-disease-japan-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Related Reports:
Alzheimer's Disease Pipeline Insights, DelveInsight
"Alzheimer's Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Alzheimer's Disease market. A detailed picture of the Alzheimer's Disease pipeline landscape is provided, which includes the disease overview and Alzheimer's Disease treatment guidelines.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=alzheimers-disease-market-epidemiology-therapies-companies-delveinsight-biogeneisai-biovie-ab-science-eli-lilly-and-company-cassava-sciences-taurx-therapeutics-novo-nordisk-keiferx-eli]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Alzheimer's Disease Market: Epidemiology, Therapies, Companies, DelveInsight | Biogen/Eisai, BioVie, AB Science, Eli Lilly and Company, Cassava Sciences, TauRx Therapeutics, Novo Nordisk, KeifeRx, Eli here
News-ID: 4227947 • Views: …
More Releases from ABNewswire
TCL Offers Unmatched Discounts on NXTPAPER 11 Gen 2 Tablets for a Limited Time
Image: https://www.abnewswire.com/upload/2025/11/7d28d258c990d6d6d333a09d1195a4d9.jpg
TCL is making eye comfort more affordable than ever this Black Friday, with both configurations of its NXTPAPER 11 Gen 2 tablet [https://www.amazon.com/dp/B0FG7FRDPL?maas=maas_adg_F465400792B3CDBEB55FE9291F5841A8_afap_abs&ref_=aa_maas&tag=maas] seeing record-low prices on Amazon. From now through December 1, the 64 GB version is down to $159.99 (36% off), and the 128 GB version is just $179.99 (38% off).
The NXTPAPER 11 Gen 2 stands out for its paper-like 11-inch Full HD+ display, powered by TCL's…
TCL offers exceptional deal making NXTPAPER 11 Plus tablet affordable under 300$
If you're looking for a tablet that balances performance, comfort, and value, the NXTPAPER 11 Plus from TCL [https://www.amazon.com/dp/B0FLJMFNR7?maas=maas_adg_5AF2681E26EC62C74DF5C1C72CE6A9DD_afap_abs&ref_=aa_maas&tag=maas] is shaping up to be one of this year's smartest buys. With the Black Friday sale underway, you can snag it for just $249.99.
Image: https://www.abnewswire.com/upload/2025/11/da5f5868666d07b1b589c9593af7a59f.jpg
The 11.5" 2.2K resolution screen uses TCL's proprietary NXTPAPER 4.0 technology, designed to reduce glare, cut blue-light emission, and deliver a more "paper-like" reading experience - ideal…
TCL Unveils Exceptional Offer on the Advanced NXTPAPER 11 Gen 2 Tablet
If you're on the lookout for an affordable tablet this Black Friday that's easy on the eyes, the TCL NXTPAPER 11 Gen 2 (128 GB) [https://www.amazon.com/dp/B0FG7QV6SF?maas=maas_adg_1486FCD4C758EA9A35182092D196F846_afap_abs&ref_=aa_maas&tag=maas] is now a serious contender - and with its current deal, it's one to watch.
Image: https://www.abnewswire.com/upload/2025/11/1c870dfdbb5765161f68d40f15583e4c.jpg
Original price: $289.99
Black Friday price: $179.99 - that's 38% off (about $110 off)
Deal runs from November 20 through December 1, 2025, available on Amazon.
Eye-friendly NXTPAPER display: The NXTPAPER 4.0…
Arabian Ranches 2 Dubai Lifestyle and Community Insights
Image: https://www.abnewswire.com/upload/2025/11/f05e5fe29252be6e415fae48b211f699.jpg
Introduction
Morning activity sets the tone for the Arabian Ranches 2 lifestyle [https://www.luxuryproperty.com/dubai/villa-for-rent/arabian-ranches-2]. The streets stay calm as joggers move along the shaded paths, and families gather at the parks before school buses arrive. You feel the structure and comfort that define Dubai family communities. Life slows down after you pass the gates. The streets stay organized, and the parks stay active throughout the day. This setting shows the true…
More Releases for Alzheimer
Alzheimer Therapeutics Market Breakthrough Innovations and Increasing Treatment …
The Alzheimer Therapeutics Market is rapidly evolving as disease-modifying therapies, early-stage diagnostic tools, and biomarker-driven treatment approaches reshape global management of Alzheimer's disease (AD). As one of the most prevalent neurodegenerative conditions, Alzheimer's affects millions of older adults worldwide. With recent regulatory approvals of anti-amyloid monoclonal antibodies, enhanced imaging technology, and increased R&D investment, the market is experiencing unprecedented momentum.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/51928
Key Takeaways
• Disease-modifying…
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
